Jill Alldredge, MD, discusses the toxicities associated with PARP inhibition and the management of those adverse effects in patients with ovarian cancer.
Jill Alldredge, MD
Advertisement
Articles by Jill Alldredge, MD
Jill Alldredge, MD, discusses the management of symptoms in patients with ovarian cancer during treatment with a PARP inhibitor.
Advertisement
Latest Updated Articles
Dr. Alldredge on Managing AEs With PARP Inhibitors in Ovarian CancerJanuary 24th 2023
Advertisement
Advertisement
Trending on OncLive
1
HERIZON-GEA-01 PD-L1 Subgroup Data Support Zanidatamab Combo as a New Frontline SOC in HER2+ GEA
2
Antibody-Drug Conjugates in Lung Cancer: The Tip of the Iceberg
3
Selinexor Plus Ruxolitinib Yields Superior Spleen Responses, OS Signal in JAK Inhibitor–Naïve Myelofibrosis
4
TALAPRO-3 Shows Talazoparib Plus Enzalutamide Improves rPFS in HRR-Altered mCSPC
5